| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60937dc1a7e9f635986c5a7be88b607d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_83614030a5e4d48eb36f5234281c0f60 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55583
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6018 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385 |
| filingDate |
2010-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4e0eee7452c4bc1c71d650776ef6aa6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aedae8b4215dd99c5284e1a7e8dd4f4b |
| publicationDate |
2012-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2012070458-A1 |
| titleOfInvention |
Adjuvanting meningococcal factor h binding protein |
| abstract |
Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10328142-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10376573-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012064103-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10245311-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10568953-B2 |
| priorityDate |
2009-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |